Education
About Us
Working with TipRanks
Follow Us
Lucid Diagnostics (LUCD)
NASDAQ:LUCD
LUCD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.66 - $1.80
Previous CloseN/A
Volume130.18K
Average Volume (3M)1.26M
Market Cap
$140.16M
Enterprise Value$101.11M
Total Cash (Recent Filing)$39.52M
Total Debt (Recent Filing)$13.78M
Price to Earnings (P/E)―
Beta0.27
Next Earnings
May 19, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding105,382,960
10 Day Avg. Volume1,768,357
30 Day Avg. Volume1,259,298
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)28.19
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.04
Enterprise Value/Ebitda-2.28
Forecast
1Y Price Target
$3.75Price Target Upside181.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Lucid Diagnostics News
PremiumCompany Announcements
Lucid Diagnostics Closes $16.1 Million Public Offering
PremiumCompany Announcements
Lucid Diagnostics Announces Public Stock Offering---
Bulls Say, Bears Say
Bulls Say
Earnings And Revenue GrowthLucid Diagnostics turned in a solid Q4 volume beat, and for 2024, turned in +79% Y/Y revenue growth, driven by +41% and +32% Y/Y growth in volumes and ASPs, respectively.
Insurance CoverageLucid obtained positive commercial insurance coverage for EsoGuard from Highmark Blue Cross Blue Shield (BSBS) of NY.
Regulatory ApprovalsThe company has reached a milestone in its regulatory pathway by submitting its clinical data package for Medicare coverage, which is expected to significantly increase adoption.
Bears Say
Operating ExpensesLUCD's operating expenses were modestly above the analyst's estimate.
Reimbursement CriteriaNo current test has yet achieved the criteria for reimbursement eligibility, including analytic validity, clinical validity, and clinical utility data.
Revenue ChallengesLUCD missed consensus revenue despite having grown test volume significantly as collections lagged test volume.
---
Ownership Overview
4.34% Insiders
0.73% Mutual Funds
1.66% Other Institutional Investors
92.49% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
LUCD FAQ
What was Lucid Diagnostics’s price range in the past 12 months?
Lucid Diagnostics lowest stock price was $0.66 and its highest was $1.80 in the past 12 months.
What is Lucid Diagnostics’s market cap?
Lucid Diagnostics’s market cap is $140.16M.
When is Lucid Diagnostics’s upcoming earnings report date?
Lucid Diagnostics’s upcoming earnings report date is May 19, 2025 which is in 23 days.
How were Lucid Diagnostics’s earnings last quarter?
Lucid Diagnostics released its earnings results on Mar 24, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.178 by -$0.012.
Is Lucid Diagnostics overvalued?
According to Wall Street analysts Lucid Diagnostics’s price is currently Undervalued.
Does Lucid Diagnostics pay dividends?
Lucid Diagnostics does not currently pay dividends.
What is Lucid Diagnostics’s EPS estimate?
Lucid Diagnostics’s EPS estimate is -0.14.
How many shares outstanding does Lucid Diagnostics have?
Lucid Diagnostics has 105,382,960 shares outstanding.
What happened to Lucid Diagnostics’s price movement after its last earnings report?
Lucid Diagnostics reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.178. Following the earnings report the stock price went down -1.316%.
Which hedge fund is a major shareholder of Lucid Diagnostics?
Currently, no hedge funds are holding shares in LUCD
---
Lucid Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.75 (181.95% Upside)
$3.75 (181.95% Upside)
Blogger Sentiment
Bullish
LUCD Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 13.9%
Last 30 Days ▲ 13.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
94.72%
12-Months-Change
Fundamentals
Return on Equity
-2956.43%
Trailing 12-Months
Asset Growth
12.63%
Trailing 12-Months
Company Description
Lucid Diagnostics
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
---
LUCD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong positive outlook with significant advancements in test volume, insurance coverage, and clinical validation. The company's financial position is strong, bolstered by recent financing. However, challenges remain in revenue recognition and the reimbursement environment, which are expected to improve with strategic efforts underway.Read More>---
LUCD Stock 12 Month Forecast
Average Price Target
$3.75
▲(181.95% Upside)
Technical Analysis
Nektar Therapeutics
―
Greenwich LifeSciences
―
EUDA Health Holdings
―
Lexeo Therapeutics, Inc.
―
BioAge Labs, Inc.
―
Best Analysts Covering LUCD
1 Year
1 Year Success Rate
7/20 ratings generated profit
1 Year Average Return
-20.02%
reiterated a buy rating 16 days ago
Copying Michael Matson's trades and holding each position for 1 Year would result in 35.00% of your transactions generating a profit, with an average return of -20.02% per trade.
---